Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 17, Issue 2, Pages 49-57
http://dx.doi.org/10.1155/2001/327047

Cancer Proteomics: The State of the Art

Paul C. Herrmann,1 Lance A. Liotta,1 and Emanuel F. Petricoin III2

1Clinical Proteomics Program, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
2Clinical Proteomics Program, Division of Therapeutic Proteins, CBER, Food and Drug Administration, Bethesda, MD 20892, USA

Received 20 September 2001; Accepted 20 September 2001

Copyright © 2001 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Paul C. Herrmann, Lance A. Liotta, and Emanuel F. Petricoin III, “Cancer Proteomics: The State of the Art,” Disease Markers, vol. 17, no. 2, pp. 49-57, 2001. https://doi.org/10.1155/2001/327047.